Original Articles
Early Access
Correlation of prognostic biomarkers with histologic features in Albanian women with breast cancer
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 12 May 2025
Accepted: 4 November 2025
Accepted: 4 November 2025
162
Views
40
Downloads
Authors
Breast cancer is the leading cause of cancer among women and remains one of the most prevalent contributors to cancer-related mortality worldwide. This study aims to evaluate biomarker expression in women with breast cancer and the correlations between them and other prognostic parameters. A retrospective analysis of 252 subjects was conducted at the Oncology Department of Mother Teresa University Hospital in Albania between 2021 and 2024. The highest rate of the disease was observed in the over-45 age group (92.5%). A family history of cancer was reported in 13.9% of patients. The most common histological type identified was ductal carcinoma (81.3%), which predominantly affected the left breast (57.1%) and was most frequently stage 2 (69.8%). A significant association (p < 0.001) was found between disease stage and expression of ER (Estrogen Receptors), PR (Progesterone Receptors), and HER2 (Human Epidermal Growth Factor Receptor 2), as well as between patient age and expression of ER, PR, and HER2 receptors (p = 0.02). HER2 and Ki-67 expression were inversely associated with ER and PR. Ki-67 was significantly correlated with age (p = 0.008) and stage (p < 0.001). Nodal metastasis correlated with Ki-67 (p = 0.02) and ER (p = 0.01).
Downloads
Download data is not yet available.
Citations
1. Esmat E, Haidary AM, Saadaat R, et al. Association of hormone receptors and human epidermal growth factor receptor-2/neu expressions with clinicopathologic factors of breast carcinoma: a cross-sectional study in a tertiary care hospital, Kabul, Afghanistan. BMC Cancer 2024;24:388.
2. Falck AK, Fernö M, Bendahl PO, Rydén L. St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases – aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial. BMC Cancer 2013;13:558.
3. Yahiji AM, Prihantono P, Kusuma MI, et al. Comparison of clinical-pathological features, 5-year disease-free survival, and overall survival among various breast cancer hormone receptor statuses. Chirurgia 2025;38:139.
4. García Fernández A, Giménez N, Fraile M, et al. Survival and clinicopathological characteristics of breast cancer patients according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. Breast 2012;21:366-73.
5. Davey MG, Hynes SO, Kerin MJ, et al. Ki-67 as a prognostic biomarker in invasive breast cancer. Cancers (Basel) 2021;13:4455.
6. Xi X, Huang XW, Yuan HZ, et al. Biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastases. Oncol Lett 2020;20:1-1.
7. Fumagalli C, Barberis M. Breast cancer heterogeneity. Diagnostics (Basel) 2021;11:1555.
8. Łukasiewicz S, Czeczelewski M, Forma A, et al. Breast cancer - epidemiology, risk factors, classification, prognostic markers, and current treatment strategies - an updated review. Cancers (Basel) 2021;13:4287.
9. Grann VR, Troxel AB, Zojwalla NJ, et al. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 2005;103:2241-51.
10. Rubin E, Shan K, Dalal S, et al. Molecular targeting of the human epidermal growth factor receptor-2 (HER2) genes across various cancers. Int J Mol Sci 2024;25:1064.
11. Lee J, Lee YJ, Bae SJ, et al. Ki-67, 21-gene recurrence score, endocrine resistance, and survival in patients with breast cancer. JAMA Netw Open 2023;6:e2330961.
12. Allred DC. Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer. Mod Pathol 2010;23:S52-9.
13. Arun B, Couch FJ, Abraham J, et al. BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing. Br J Cancer 2024;131:1400-14.
14. Lee A, Moon BI, Kim TH. BRCA1/BRCA2 pathogenic variant breast cancer: treatment and prevention strategies. Ann Lab Med 2020;40:114-21.
15. Xhetani M, Hasa A, Laze B. BRCA1 mutations in family members with breast cancer history. SpringerNature 2024;913-13.
16. Xhetani M, Gjoka J, Bakiri F, et al. Evaluation of breast cancer awareness and perception among women in Albania. European Human Genetics Conference; 2022; 11-14.
17. Malainou CP, Stachika N, Damianou AK, et al. Estrogen-receptor-low-positive breast cancer: pathological and clinical perspectives. Curr Oncol 2023;30:9734-45.
18. Schrodi S, Braun M, Andrulat A, et al. Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort. Ann Oncol 2021;32:1410-24.
19. Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2023;147:993-1000.
20. Liang Q, Ma D, Gao RF, Yu KD. Effect of Ki-67 expression levels and histological grade on breast cancer early relapse in patients with different immunohistochemical-based subtypes. Sci Rep 2020;10:7648.
21. McGuire A, Brown J, Malone C, et al. Effects of age on the detection and management of breast cancer. Cancers (Basel) 2015;7:908-29.
22. Nisa A, Bhurgri Y, Raza F, Kayani N. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pac J Cancer Prev 2008;9:553-6.
23. Ellis IO, Galea M, Broughton N, et al. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 1992;20:479-89.
24. Senel F. The hormone receptor status in breast cancer and the relationship of subtypes with clinicopathological features. Indian J Pathol Microbiol 2021;64:671-6.
25. Yip CH, Rhodes A. Estrogen and progesterone receptors in breast cancer. Future Oncol 2014;10:2293-301.
26. Khabaz MN. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the west of Saudi Arabia? Asian Pac J Cancer Prev 2014;15:8395-400.
27. Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst 2015;107:djv048.
28. Benz CC. Impact of aging on the biology of breast cancer. Crit Rev Oncol Hematol 2008;66:65-74.
29. Järvinen TAH, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor β is coexpressed with ERα and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 2000;156:29-35.
30. Dayal A, Shah RJ, Kothari S, Patel SM. Correlation of Her-2/neu status with estrogen, progesterone receptors and histologic features in breast carcinoma. Ann Pathol Lab Med 2016;3:476-83.
31. Bhagat VM, Jha BM, Patel PR. Correlation of hormonal receptor and Her-2/neu expression in breast cancer: a study at tertiary care hospital in South Gujarat. Natl J Med Res 2012;2:295-8.
32. Guo L, Kong D, Liu J, et al. Breast cancer heterogeneity and its implication in personalized precision therapy. Exp Hematol Oncol 2023;12:3.
33. Elkablawy MA, Albasri AM, Mohammed RA, et al. Ki67 expression in breast cancer: correlation with prognostic markers and clinicopathological parameters in Saudi patients. Saudi Med J 2016;37:137-41.
34. Marwah N, Batra A, Marwah S, et al. Correlation of proliferative index with various clinicopathologic prognostic parameters in primary breast carcinoma: a study from North India. J Cancer Res Ther 2018;14:537-42.
35. Hu X, Chen W, Li F, et al. Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance. Front Oncol 2023;13:1053125.
36. Parl FF, Schmidt BP, Dupont WD, Wagner RK. Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer 1984;54:2237-42.
How to Cite
Correlation of prognostic biomarkers with histologic features in Albanian women with breast cancer. (2026). Journal of Biological Research - Bollettino Della Società Italiana Di Biologia Sperimentale. https://doi.org/10.4081/jbr.2026.13977
Copyright (c) 2026 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.